Drug Trial Radar · NCT02256436
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Last checked: Nov 19, 2026Latest source record: Sep 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
542
Actual
Start
Oct 22, 2014
Primary completion
Sep 7, 2016
Study completion Oct 1, 2020
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 3, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Participants with metastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy will be randomly assigned to receive Investigator's choice of paclitaxel, docetaxel, or vinflunine (Control), or pembrolizumab. The primary study hypotheses are that pembrolizumab will prolong Overall Survival (OS) and Progression-free Survival (PFS) compared to paclitaxel, docetaxel, or vinflunine.
Conditions
- Urothelial Cancer
Interventions
pembrolizumabBiological
IV infusion
paclitaxelDrug
IV infusion
vinflunineDrug
IV infusion
docetaxelDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - All ParticipantsTime frame: Through primary analysis database cut-off date of 07-Sep-2016 (Up to approximately 20 months)
- Overall Survival (OS) - All ParticipantsTime frame: Through primary analysis database cut-off date of 07-Sep-2016 (Up to approximately 20 months)
- PFS Per RECIST 1.1 - Participants With Programmed Cell Death-Ligand (PD-L1) Positive TumorsTime frame: Through primary analysis database cut-off date of 07-Sep-2016 (Up to approximately 20 months)
- OS - Participants With PD-L1 Positive TumorsTime frame: Through primary analysis database cut-off date of 07-Sep-2016 (Up to approximately 20 months)
- PFS Per RECIST 1.1 - Participants With Strongly PD-L1 Positive TumorsTime frame: Through primary analysis database cut-off date of 07-Sep-2016 (Up to approximately 20 months)
- OS - Participants With Strongly PD-L1 Positive TumorsTime frame: Through primary analysis database cut-off date of 07-Sep-2016 (Up to approximately 20 months)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.